.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Citi
Healthtrust
Cantor Fitzgerald
Deloitte
Accenture
QuintilesIMS
Dow
Cipla
Julphar

Generated: December 14, 2017

DrugPatentWatch Database Preview

COMETRIQ Drug Profile

« Back to Dashboard

Which patents cover Cometriq, and when can generic versions of Cometriq launch?

Cometriq is a drug marketed by Exelixis and is included in one NDA. There are three patents protecting this drug.

This drug has one hundred and twenty-five patent family members in twenty-eight countries and twelve supplementary protection certificates in nine countries.

The generic ingredient in COMETRIQ is cabozantinib s-malate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the cabozantinib s-malate profile page.

Summary for COMETRIQ

Drug patent expirations by year for COMETRIQ

Pharmacology for COMETRIQ

Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
ExelixisCOMETRIQcabozantinib s-malateCAPSULE;ORAL203756-001Nov 29, 2012RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
ExelixisCOMETRIQcabozantinib s-malateCAPSULE;ORAL203756-002Nov 29, 2012RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
ExelixisCOMETRIQcabozantinib s-malateCAPSULE;ORAL203756-001Nov 29, 2012RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
ExelixisCOMETRIQcabozantinib s-malateCAPSULE;ORAL203756-002Nov 29, 2012RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
ExelixisCOMETRIQcabozantinib s-malateCAPSULE;ORAL203756-001Nov 29, 2012RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
ExelixisCOMETRIQcabozantinib s-malateCAPSULE;ORAL203756-001Nov 29, 2012RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
ExelixisCOMETRIQcabozantinib s-malateCAPSULE;ORAL203756-002Nov 29, 2012RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
ExelixisCOMETRIQcabozantinib s-malateCAPSULE;ORAL203756-001Nov 29, 2012RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
ExelixisCOMETRIQcabozantinib s-malateCAPSULE;ORAL203756-002Nov 29, 2012RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
ExelixisCOMETRIQcabozantinib s-malateCAPSULE;ORAL203756-002Nov 29, 2012RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: COMETRIQ

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,809,549Malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'(4-fluorophenyl)cycl- opropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer► Subscribe
2,014,155,378► Subscribe
9,174,947c-Met modulators and methods of use► Subscribe
8,476,298c-Met modulators and method of use► Subscribe
8,497,284C-met modulators and method of use► Subscribe
8,178,532c-Met modulators and method of use► Subscribe
8,067,436c-Met modulators and methods of use► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: COMETRIQ

Country Document Number Estimated Expiration
Australia2017200555► Subscribe
European Patent Office2673262► Subscribe
China102388024► Subscribe
China106083714► Subscribe
Japan5694501► Subscribe
Cyprus1112056► Subscribe
South Korea20140044782► Subscribe
Denmark2210607► Subscribe
New Zealand712808► Subscribe
Cyprus1114007► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: COMETRIQ

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014000091Germany► SubscribePRODUCT NAME: CABOZANTINIB UND JEDES THERAPEUTISCHE AEQUIVALENT HIERVON WIE DURCH DAS GRUNDPATENT GESCHUETZT, EINSCHLIESSLICH PHARMAZEUTISCH ANNEHMBARER SALZE; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140321
2014033Lithuania► SubscribePRODUCT NAME: CABOZANTINIBUM; REGISTRATION NO/DATE: EU/1/13/890/001 - EU/1/13/890/003 20140321
0140029 00117Estonia► SubscribePRODUCT NAME: KABOSANTINIIB;REG NO/DATE: K(2014)2043 (LOPLIK) 26.03.2014
0 50007-2014Slovakia► SubscribePRODUCT NAME: CABOZANTINIB; REGISTRATION NO/DATE: EU/1/13/890/001 - EU/1/13/890/003 20140326
508Luxembourg► SubscribePRODUCT NAME: CABOZANTINIB ET TOUTES LES FORMES THERAPEUTIQUEMENT EQUIVALENTES QUI EN DERIVENT TELLES QUE PROTEGEES PAR LE BREVET DE BASE, Y COMPRIS LES SELS PHARMACEUTIQUEMENT ACCEPTABLES. FIRST REGISTRATION: 20140326
90053-4Sweden► SubscribePRODUCT NAME: CABOZANTINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/13/890 20140326
C0067France► SubscribePRODUCT NAME: CABOZANTINIB ET TOUTE FORME THERAPEUTIQUEMENT EQUIVALENTE COUVERTE PAR LE BREVET DE BASE,INCLUANT SES SELS PHARMACEUTIQUEMENT EQUIVALENTS.; REGISTRATION NO/DATE: EU/1/13/890 20140326
2014 00039Denmark► SubscribePRODUCT NAME: CABOZANTINIB, INKLUSIVE FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER CABOZANTINIB (S)-MALAT; REG. NO/DATE: EU/1/13/890/001-003 20140326
2014 00039Denmark► SubscribePRODUCT NAME: CABOZANTINIB, INKLUSIVE FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER CABOZANTINIB (S)-MALAT; REG. NO/DATE: EU/1/13/890/001-003 20140321
2014033,C2213661Lithuania► SubscribePRODUCT NAME: KABOZANTINIBAS IR JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS; REGISTRATION NO/DATE: EU/1/13/890/001 - EU/1/13/890/003 20140321
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Colorcon
Moodys
Chubb
Daiichi Sankyo
Johnson and Johnson
Julphar
AstraZeneca
Fish and Richardson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot